The unpublished phase III MORPHO study (BMT CTN 1506) randomized 356 patients to two years of gilteritinib (120mg per day) starting 30-90 days post-alloHSCT vs placebo in adults with FLT3-ITD AML in CR1. This evidence concerns the gene FLT3 and acute myeloid leukemia.